###begin article-title 0
HLA-DQB1 Allele and Hypocretin in Korean Narcoleptics with Cataplexy
###end article-title 0
###begin p 1
###xml 879 880 879 880 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 989 990 989 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1195 1196 1193 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 453 461 <span type="species:ncbi:9606">patients</span>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
###xml 738 746 <span type="species:ncbi:9606">patients</span>
###xml 784 792 <span type="species:ncbi:9606">patients</span>
###xml 1030 1038 <span type="species:ncbi:9606">patients</span>
###xml 1138 1146 <span type="species:ncbi:9606">patients</span>
Cataplexy is one of the most pathognomonic symptoms in narcolepsy. This study was designed to investigate the frequency of the HLA-DQB1 allele and cerebrospinal fluid (CSF) hypocretin levels in Korean narcoleptics with cataplexy as compared with those who do not have cataplexy. Seventy-two narcoleptics were selected based on polysomnography and multiple sleep latency test as well as their history and clinical symptoms at Sleep Disorders Clinic. The patients were divided into a narcolepsy with cataplexy group (n=56) and a narcolepsy without cataplexy group (n=16). All patients were subjected to HLA typing to determine the frequency of DQB1 allele and to spinal tapping to measure the level of CSF hypocretin. In cataplexy-positive patients, as compared with cataplexy-negative patients, the frequency of HLA-DQB1*0602 was found to be significantly high (89.3% vs. 50.0%) (p=0.003). On the other hand, the frequency of HLA-DQB1*0601 was found to be significantly low (0% vs. 43.8%) (p<0.001). In 48 of 56 cataplexy-positive patients (85.7%), hypocretin levels were decreased (</=110 pg/mL). However, only 6 of 16 cataplexy-negative patients (37.5%) exhibited a decreased hyopcretin level (p<0.001). The high frequency of HLA-DQB1*0602, low frequency of HLA-DQB1*0601 and low hypocretin levels in cataplexy-positive groups suggest that cataplexy-positive narcolepsy might be an etiologically different disease entity from the cataplexy-negative.
###end p 1
###begin title 2
INTRODUCTION
###end title 2
###begin p 3
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 308 309 308 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1196 1197 1196 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1199 1200 1199 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
Cataplexy is a symptom that occurs when the muscle tension in various areas of the body is suddenly decreased involuntarily and lasts from few seconds to several minutes. It is a pathognomonic symptom of narcoplepsy, generally induced in response to laugh, excitement, anger, and other emotional changes (1, 2). In addition, among excessive daytime sleepiness, cataplexy, hypnagogic hallucination, sleep paralysis and nocturnal sleep disorder, which are known to be a symptom pentad of narcolepsy, cataplexy has been known to be a prerequisite clinical symptom required for the diagnosis of narcolepsy according to the International Classification of Sleep Disorders (3). In the absence of cataplexy, the diagnosis of broad-spectrum narcolepsy is possible by the presence of other clinical symptoms of narcolepsy and the result of multiple sleep latency test. On the other hand, for the diagnosis of narrow-spectrum narcolepsy, the presence of cataplexy is essential and the narcolepsy with cataplexy is considered to be an etiologically homogeneous disease. Especially, in cases where cataplexy is either clinically typical or severe, the frequency of HLA-DQB1*0602 has been shown to be higher (4, 5).
###end p 3
###begin p 4
###xml 318 319 318 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 536 537 536 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 655 656 655 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1136 1141 1136 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-fos</italic>
###xml 1225 1230 1225 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-fos</italic>
###xml 1359 1361 1359 1361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 787 791 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
###xml 827 835 <span type="species:ncbi:9606">patients</span>
Hypocretin is a pair of neuropeptides discovered in the hypothalamus in 1998, consisting of hypocretin-1 (Hcrt 1) and hypocretin-2 (Hcrt 2), and it has been shown that they bind to the G protein-coupled receptors, hypocretin-1 receptor (Hcrtr 1), and hypocretin receptor-2 (Hcrtr 2), increasing intracellular calcium (6, 7). At the time of its discovery, hypocretin has been introduced as a neuropeptide that increases appetite and is involved in the regulation of body temperature, endocrine function, the cardiovascular system, etc. (8). More recently, the report that showed canine narcolepsy is caused by a mutation in the hypocretin-2 receptor gene (9, 10), and the report that showed behavioral patterns and the electroencephalographic findings in preprohypocretin knock-out white rats are similar to those of narcolepsy patients (11) draw attention to the association of hypocretin and narcolepsy. Subsequently, it has been shown that hypocretin nerve cells mediate excitatory action on monoaminergic neurons and thereby they are involved in the normal sleep awake cycle (12). In addition, it was reported that the expression of c-fos was increased in hypocretin neurons, during the awake period and the expression of c-fos is decreased in hypocretin neurons during the NREM sleep period, indicating the association of hypocretin and sleep regulation (13).
###end p 4
###begin p 5
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 558 560 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 562 564 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 88 93 <span type="species:ncbi:9606">human</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 367 375 <span type="species:ncbi:9606">patients</span>
Until now, the mutation in the preprohypocretin gene or the hypocretin receptor gene in human narcolepsy has not been detected (14). However, it has been reported that in most narcolepsy patients, 80-90% of hypocretin cells in the hypothalamus were destroyed (15), and the transcription of preprohypocretin mRNA was significantly decreased in the brain of narcolepsy patients (14). Along with these findings, the report showing the concentration of hypocretin in the cerebrospinal fluid (CSF) was measured below the detection limit in over 80% narcoleptics (16, 17) suggests that hypocretin deficiency may be one of the most important pathophysiologic mechanisms of narcolepsy.
###end p 5
###begin p 6
###xml 194 202 <span type="species:ncbi:9606">patients</span>
In this regard, this study was performed on narcoleptics diagnosed by polysomnography and multiple sleep latency test (MSLT) to understand the pathophysiology of narcolepsy in Korean narcolepsy patients by examining the frequency of HLA-DQB1 allele and the concentration of CSF hypocretin. In addition, this study was designed to investigate the frequency of the HLA-DQB1 allele and CSF hypocretin levels in Korean narcoleptics with cataplexy as compared with those who have not cataplexy.
###end p 6
###begin title 7
MATERIALS AND METHODS
###end title 7
###begin title 8
Subjects
###end title 8
###begin p 9
###xml 238 239 238 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
###xml 377 385 <span type="species:ncbi:9606">patients</span>
From August 2003 to July 2005, among the patients reporting excessive daytime sleepiness, those who were suspicious of having narcolepsy were selected, based on diagnostic criteria for The International Classification of Sleep Disorders (3), and polysomnography and MSLT were performed at Sleep Disorders Clinic of St. Vincent's Hospital, The Catholic University of Korea. All patients with a chief complaint of excessive daytime sleepiness not obviously from sleep disordered breathing (SDB), delayed sleep-phase syndrome or behaviorally-induced insufficient sleep syndrome were included. Seventy-five subjects were selected, who had at least 2 sleep onset REM periods (SOREMPs) on MSLT, and the mean sleep latency shorter than 5 min. And in polysomnography, they did not have any evidence of sleep disorders that can cause excessive daytime sleepiness such as sleep apnea syndrome, periodic limb movement disorder, etc. Seventy-two of the seventy-five subjects (96%) accepted further evaluation, including blood and CSF tests.
###end p 9
###begin p 10
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Seventy-two narcoleptic patients underwent HLA typing to derermine the DQB1 allele and spinal tapping to derermine the level of CSF hypocretin. The study subjects were divided into a narcolepsy with cataplexy group (n=56) and a narcolepsy without cataplexy group (n=16) according to the presence or absence of cataplexy. Narcoleptics were excluded if they had a personal history of medical illness that may affect sleep, substance or alcohol abuse, seizure disorder, definite neurological deficit, and mental disorder that may cause sleep abnormalities. This study was approved by the institutional review board of the St. Vincent's Hospital, The Catholic University of Korea. Informed consent was obrained according to the Declaration of Helsinki.
###end p 10
###begin title 11
Methods
###end title 11
###begin p 12
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 90 97 <span type="species:ncbi:9606">patient</span>
All clinical symptoms of narcolepsy were collected through a structured interview in each patient by psychiatrists who had completed the sleep medicine course and through a sleep questionnaire. The structured interview revealed the frequency of excessive daytime sleepiness, cataplexy, sleep paralysis, hypnagogic hallucination, and the characteristic of cataplexy. In the questionnaire, triggering factors, duration, frequency of cataplexy were included, and the Stanford Center for Narcolepsy Sleep Inventory (18) consisting of total 146 questions was used.
###end p 12
###begin p 13
###xml 46 47 46 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Lymphocytes were isolated from the blood (2x106 cells/mL), and 0.5 mL PCR-K buffer (10x PCR buffer 1 mL, NP-40 40 microL, Tween-20 45 microL, proteinase K (20 mg/mL) 30 microL, D/W 8.8 mL) was added, and dissolved by treating at 58℃ for 60 min, and treated at 95℃ for 10 min, to inactivate proteinase K, and DNA was extracted. To determine the HLA-DQB1 allele, allele-specific probes were labeled with Dig-11-dUTP using terminal transferase, each sample was dropped on a Nylon membrane, Dig-11-dUTP labeled allele-specific probe was hybridized with the membrane dropped a sample, the expression was assessed using anti-DIG antibody, and finally the genotypes were determined.
###end p 13
###begin p 14
###xml 170 173 170 173 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">125</sup>
Between 11 a.m. and 4 p.m., CSF was collected by lumbar puncture, and immediately stored frozen at -70℃ until the measurement of hypocretin. Hypocretin-1 was measured by 125I radioimmunoassay (RIA) kit (hypocretin-1: Phoenix Pharmaceuticals, Mountain View, CA, U.S.A.). CSF was acidified with the same volume of 0.1% trifluoroacetic acid (TFA), purified using equilibriated C-18 Sep-Columns (Phoenix Pharmaceuticals), and the columns were washed with 0.1% TFA twice and eluted with 3 mL of the mixture of 0.1% TFA and 60% acetonitrile (HPLC grade). The eluted solution was dried by applying negative pressure, and the pellets produced were dissolved with 300 microL RIA buffer. The detection limit was 40 pg/mL, and all samples were measured in duplicate.
###end p 14
###begin title 15
Statistical analyses
###end title 15
###begin p 16
###xml 344 345 342 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
Statistical analysis was performed using SPSS for Windows (Version 10.0). Demographic data, the frequency of clinical symptoms, and the HLA-DQB1 allele frequencies were presented as the mean+/-standard deviation, as well as in percentage. These variables and the CSF hypocretin levels were analyzed by independent t-test and chi-square test. A p-value less than 5% was considered statistically significant.
###end p 16
###begin title 17
RESULTS
###end title 17
###begin title 18
Demographical characteristics
###end title 18
###begin p 19
###xml 200 201 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
Of the total 72 patients, 47 were male patients (65.3%), and 25 were female patients (34.7%). The age distribution was 7-68 yrs (mean age 26.4+/-11.6 yrs). The mean body mass index was 24.2+/-3.7 kg/m2, and the mean duration of illness was 9.5+/-8.3 yr.
###end p 19
###begin p 20
###xml 216 217 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
The narcolepsy with cataplexy group consisted of 34 male patients (60.7%) and 22 female patients (39.3%). The age distribution was 7 to 59 yrs (mean age: 25.4+/-10.4 yrs). The mean body mass index was 24.5+/-3.7 kg/m2, and the mean duration of illness was 9.9+/-8.8 yr.
###end p 20
###begin p 21
###xml 214 215 210 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 350 357 344 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 60 68 <span type="species:ncbi:9606">patients</span>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
The narcolepsy without cataplexy group consisted of 13 male patients (81.3%) and 3 female patients (18.8%). The age distribution was 8-68 yrs (mean age 29.8+/-14.8 yrs). The mean body mass index was 23.1+/-3.8 kg/m2. The mean duration of illness was 8.3+/-6.2 yr. No significant differences were observed in demographic variables between two groups (Table 1).
###end p 21
###begin title 22
Clinical symptoms
###end title 22
###begin p 23
###xml 49 57 <span type="species:ncbi:9606">patients</span>
###xml 120 128 <span type="species:ncbi:9606">patients</span>
###xml 169 177 <span type="species:ncbi:9606">patients</span>
###xml 229 237 <span type="species:ncbi:9606">patients</span>
Excessive daytime sleepiness was shown in all 72 patients (100%), and it was found that cataplexy was experienced in 56 patients (77.8%), hypnagogic hallucination in 40 patients (55.6%), and sleep paralysis was experienced in 40 patients (55.6%).
###end p 23
###begin p 24
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 447 454 447 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">Table 2</xref>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 387 395 <span type="species:ncbi:9606">patients</span>
###xml 410 418 <span type="species:ncbi:9606">patients</span>
###xml 428 436 <span type="species:ncbi:9606">patients</span>
Hypnogogic hallucination was occurring more frequently in the narcolepsy with cataplexy group (36/56, 64.3%) than in the narcolepsy without cataplexy group (6/16, 25.0%) with a statistical significance (p=0.005). In addition, sleep paralysis was found to be experienced more frequently in the narcolepsy with cataplexy group, but the difference was not significant (34 patients among 56 patients [60.7%] vs. 6 patients among 16 patients [37.5%]) (Table 2).
###end p 24
###begin title 25
CSF hypocretin level
###end title 25
###begin p 26
###xml 151 153 149 151 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 356 357 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 366 373 364 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">Table 3</xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 240 248 <span type="species:ncbi:9606">patients</span>
###xml 305 313 <span type="species:ncbi:9606">patients</span>
The CSF hypocretin concentration was lower than 110 pg/mL in 54 of the total 72 patients (75.0%). The hypocretin levels were decreased (</=110 pg/mL) (19) or below the detection limit of assay (<40 pg/mL) in 48 out of 56 cataplexy-positive patients (85.7%). In comparison, only 6 of 16 cataplexy-negative patients (37.5%) had a decreased hyopcretin level (p<0.001) (Table 3).
###end p 26
###begin title 27
HLA-DQB1 Allele
###end title 27
###begin p 28
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 387 388 387 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 397 404 397 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 31 39 <span type="species:ncbi:9606">patients</span>
###xml 135 143 <span type="species:ncbi:9606">patients</span>
###xml 186 194 <span type="species:ncbi:9606">patients</span>
Of 72 narcoleptic patients, 58 patients (80.6%) had HLA-DQB1*0602. HLA-DQB1*0602 was significantly more frequent in cataplexy-positive patients (50/56, 89.3%) than in cataplexy-negative patients (8/16, 50.0%) (p<0.001). On the other hand, the frequency of HLA-DQB1*0601 was found to be significantly lower in the narcoleptics with cataplexy group (0 subjects, 0% vs. 7 subjects, 43.8%) (p<0.001) (Table 4).
###end p 28
###begin p 29
###xml 267 268 267 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 279 280 279 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 309 316 309 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">Table 4</xref>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients with a decreased CSF hypocretin level had a higher rate of HLA-DQB1*0602 (50/54, 92.6%) and a lower rate of HLA-DQB1*0601 (1/54, 1.9%) than those with a normal hypocretin level (8/18, 44.4% and 6/18, 33.3%, respectively) with a statistical significance (p<0.001 and p=0.001 for each comparison) (Table 4).
###end p 29
###begin title 30
DISCUSSION
###end title 30
###begin p 31
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 700 702 700 702 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 704 706 704 706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 892 894 892 894 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 140 148 <span type="species:ncbi:9606">patients</span>
###xml 867 874 <span type="species:ncbi:9606">patient</span>
In this study, 77.8% of the narcolepsy patients experienced cataplexy, which is in line with previous studies reporting over 70% narcolepsy patients showed cataplexy (20, 21). As the main pathophysiology of cataplexy, the imbalance between monoaminergic and cholinergic transmissions in the pons has been proposed. In addition, the cholinoceptive site in the basal forebrain has been reported to be involved in a strong emotional stimuli (22, 23). During cataplectic episodes, muscle atonia is caused by suppression of motor neurons at the spinal level, together with the loss of deep tendon reflex, H-reflex, and autonomic nervous symptoms such as increased blood pressure and decreased heart rate (23, 24). During the initial period of cataplexy, the normal wake EEG is detected, however, when cataplexy prolongs, the EEG becomes more of REM sleep pattern, and the patient recalls a dream (25). Such observations support the proposal that cataplexy is an abnormal REM sleep phenomenon. In this study, narcoleptics with cataplexy experienced more hypnagogic hallucination, another REM sleep-related symptom, as compared with narcoleptics without cataplexy. This result is thought to be a finding that confirms the association of cataplexy and REM sleep, suggesting that the narcolepsy with cataplexy and without cataplexy may be heterogeneous groups.
###end p 31
###begin p 32
###xml 54 55 54 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 64 66 64 66 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 676 677 676 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 918 920 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 228 235 <span type="species:ncbi:9606">patient</span>
As has been previously reported in other populations (4, 5, 26, 27), we also found that HLA-DQB1*0602, which has been reported to be positive in approximately 25% of the general population, was expressed 80.6% of the narcolepsy patient group. This is a result supporting the proposal that the HLA-DQB1*0602 positivity is a genetic marker for narcolepsy regardless of the racial backgrounds. In addition, the positivity of HLA-DQB1*0602 in the narcolepsy with cataplexy and without cataplexy was 89.3% and 50.0%, respectively. This result is also in agreement with previous reports that the HLA-DQB1*0602 positivity is higher in narcolepsy showing typical or severe cataplexy (4, 5, 27). In addition, we found that the HLA-DQB1*0601 allele was not expressed in the narcolepsy with cataplexy group, which is in agreement with the previous hypothesis that DQB1*0601 may serve as a protective gene against narcolepsy (28, 29). This HLA-DQB1 allelic differences between narcolepsy with cataplexy and without cataplexy may serve as the basis of the possibility that two groups may be etiologically heterogeneous.
###end p 32
###begin p 33
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 391 393 391 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 61 73 <span type="species:ncbi:9606">participants</span>
###xml 314 322 <span type="species:ncbi:9606">patients</span>
###xml 332 340 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 457 465 <span type="species:ncbi:9606">patients</span>
###xml 658 666 <span type="species:ncbi:9606">patients</span>
###xml 1025 1033 <span type="species:ncbi:9606">patients</span>
Our study also investigated the CSF hypocretin levels in all participants. We found that the deficiency of CSF hypocretin was noted in 75% of Korean narcoleptic, which is a result similar to the previous studies (16, 17). In addition, similar to previous reports that showed a low concentration of hypocretin in 9 patients among 10 patients (90%) (17), 9 patients among 11 patients (81.8%) (30), and 23 patients among 26 (88.5%) (31), our study revealed 48 patients among 56 narcoleptics with cataplexy (85.7%) had a hypocretin concentration either low (</=110 pg/mL) or lower than the detection limit (40 pg/mL), while the concentration decreased only in 6 patients among 16 narcoleptics without cataplexy (37.5%). These results raise the possibility that hypocretin deficiency may be an important pathophysiologic mechanism in the development of narcolepsy and also support the fact that narcolepsy with cataplexy and narcolepsy without cataplexy may be different diseases regarding their causality. Also, in 54 narcolepsy patients with hypocretin deficiency, as compared with narcoleptics with a normal hypocretin level (n=18), the frequency of HLA-DQB1*0602 was found to be significant high (50 subjects, 92.6% vs. 8 subjects, 44.4%) and HLA-DQB1*0601 was found to be low (1 subjects, 1.9% vs. 6 subjects 33.3%). This suggests that the CSF hypocretin concentration might be related with HLA-DQB1 allele, and HLA-DQB1*0602 and HLA-DQB1*0601 might be have an important role in developing narcolepsy.
###end p 33
###begin p 34
The limitations of our study are the absence of results from a normal control group was the small number of narcoleptics without cataplexy.
###end p 34
###begin p 35
In summary, this is the first study in Korea that investigated the association of cataplexy with HLA-DQB1 allele and hypocretin level. The high HLA-DQB1*0602 positivity, DQB1*0601 negativity, and hypocretin deficiency in narcolepsy with cataplexy in our study confirms that narcolepsy with cataplexy and narcolepsy without cataplexy are genetically and pathophysiologically different disease entities.
###end p 35
###begin p 36
###xml 46 131 46 131 <funding-source xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clinical Research Institute, St. Vincent's Hospital, The Catholic University of Korea</funding-source>
This study was supported by a grant (2005) of Clinical Research Institute, St. Vincent's Hospital, The Catholic University of Korea.
###end p 36
###begin article-title 37
Narcolepsy
###end article-title 37
###begin article-title 38
Narcolepsy
###end article-title 38
###begin article-title 39
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Extensive HLA class II studies in 58 non DRB1*15(DR2) narcoleptic patients with cataplexy
###end article-title 39
###begin article-title 40
###xml 62 70 <span type="species:ncbi:9606">patients</span>
HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients
###end article-title 40
###begin article-title 41
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
###end article-title 41
###begin article-title 42
Orexins and orexin receptors: family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviors
###end article-title 42
###begin article-title 43
Neurons containing hypocretin (orexin) project to multiple neuronal systems
###end article-title 43
###begin article-title 44
The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (Orexin) receptor 2 gene
###end article-title 44
###begin article-title 45
Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines
###end article-title 45
###begin article-title 46
###xml 30 34 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation
###end article-title 46
###begin article-title 47
Hypocretin/orexin, sleep and narcolepsy
###end article-title 47
###begin article-title 48
Fos expression in orexin neurons varies with behavioral state
###end article-title 48
###begin article-title 49
###xml 89 94 <span type="species:ncbi:9606">human</span>
A mutation in early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains
###end article-title 49
###begin article-title 50
###xml 40 45 <span type="species:ncbi:9606">human</span>
Reduced number of hypocretin neurons in human narcolepsy
###end article-title 50
###begin article-title 51
###xml 34 39 <span type="species:ncbi:9606">human</span>
Hypocretin (orexin) deficiency in human narcolepsy
###end article-title 51
###begin article-title 52
###xml 44 52 <span type="species:ncbi:9606">patients</span>
CSF hypocretin levels in Korean narcoleptic patients
###end article-title 52
###begin article-title 53
###xml 63 71 <span type="species:ncbi:9606">patients</span>
Validation of a cataplexy questionnaire in 983 sleep disorders patients
###end article-title 53
###begin article-title 54
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias
###end article-title 54
###begin article-title 55
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Subjective and polysomnographic characteristics of patients diagnosed with narcolepsy
###end article-title 55
###begin article-title 56
Sleep parameters in narcoleptics by polysomnography
###end article-title 56
###begin article-title 57
Neuropharmacology and neurochemistry of canine narcolepsy
###end article-title 57
###begin article-title 58
Pathophysiology of narcolepsy
###end article-title 58
###begin article-title 59
Investigations into the neurologic basis of narcolepsy
###end article-title 59
###begin article-title 60
Clinical aspects and features of cataplexy
###end article-title 60
###begin article-title 61
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 64 72 <span type="species:ncbi:9606">patients</span>
Expression of human leukocyte antigen (HLA) DQB1*0602 in Korean patients with narcolepsy
###end article-title 61
###begin article-title 62
The clinical features and the frequency of HLA-DQB1*0602 in Korean narcoleptics
###end article-title 62
###begin article-title 63
Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups
###end article-title 63
###begin article-title 64
###xml 37 45 <span type="species:ncbi:9606">patients</span>
HLA and hypocretin studies in Korean patients with narcolepsy
###end article-title 64
###begin article-title 65
CSF hypocretin-1 (orexin-A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia
###end article-title 65
###begin article-title 66
CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions
###end article-title 66
###begin p 67
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Demographic data of narcoleptic patients with and without cataplexy
###end p 67
###begin p 68
N, Number of subjects; NS, Not significant; BMI, body mass index. Statistical analysis was done by independent t test or chi square test.
###end p 68
###begin p 69
###xml 33 41 <span type="species:ncbi:9606">patients</span>
Clinical symptoms of narcoleptic patients with and without cataplexy
###end p 69
###begin p 70
N, Number of subjects; EDS, Excessive daytime sleepiness; NS, Not significant.
###end p 70
###begin p 71
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*p=0.005 by Pearson Chi Square Test.
###end p 71
###begin p 72
###xml 50 58 <span type="species:ncbi:9606">patients</span>
Comparison of CSF hypocretin level in narcoleptic patients with and without cataplexy
###end p 72
###begin p 73
N, Number of subjects; No., Number.
###end p 73
###begin p 74
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*p<0.001 by Pearson Chi Square Test.
###end p 74
###begin p 75
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Comparison of HLA-DQB1 allele in narcoleptic patients with and without cataplexy
###end p 75
###begin p 76
N, Number of subjects; No., Number.
###end p 76
###begin p 77
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 1 2 1 2 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 33 39 33 34 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 39 40 34 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 75 88 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8225;</sup>
###xml 88 89 71 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 120 132 103 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#167;</sup>
###xml 132 133 104 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
*p<0.001 by Fisher's Exact Test, daggerp<0.001 by Pearson Chi Square Test, double daggerp=0.001 by Fisher's Exact Test, section signp<0.001 by Fisher's Exact Test.
###end p 77

